B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
-7%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.84B
AUM Growth
+$2.84B
(-16%)
Cap. Flow
-$48.9M
Cap. Flow
% of AUM
-1.72%
Top 10 Holdings %
Top 10 Hldgs %
40.1%
Holding
86
New
10
Increased
17
Reduced
14
Closed
17
Top Buys
| 1 |
Danaher
DHR
|
$63.4M |
| 2 |
argenx
ARGX
|
$47.4M |
| 3 |
Nuvalent
NUVL
|
$42.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$38.9M |
| 5 |
Krystal Biotech
KRYS
|
$36.1M |
Top Sells
| 1 |
Guardant Health
GH
|
$64.8M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$43.2M |
| 3 |
FNA
Paragon 28, Inc.
FNA
|
$39.6M |
| 4 |
BioNTech
BNTX
|
$35.3M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
Sector Composition
| 1 | Healthcare | 67.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $132M | 4.63% | 1,191,925 +290,135 | +32% | +$32.1M |
|
2
Legend Biotech
LEGN
$6.41B
| $101M | 3.55% | 2,977,951 | – | – |
|
|
3
argenx
ARGX
$43.6B
| $95.2M | 3.35% | 160,849 +80,083 | +99% | +$47.4M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $90.9M | 3.2% | 2,709,875 -204,089 | -7% | -$6.85M |
|
5
Align Technology
ALGN
$10.3B
| $84.3M | 2.96% | 530,530 +155,351 | +41% | +$24.7M |
|
6
CG Oncology
CGON
$2.04B
| $80.4M | 2.83% | 3,283,317 | – | – |
|
|
7
Krystal Biotech
KRYS
$4.27B
| $72.3M | 2.54% | 400,744 +200,244 | +100% | +$36.1M |
|
8
Thermo Fisher Scientific
TMO
$186B
| $63.6M | 2.23% | 127,733 +37,979 | +42% | +$18.9M |
|
|
9
Danaher
DHR
$147B
| $63.4M | 2.23% | +309,339 | New | +$63.4M |
|
10
Glaukos
GKOS
$5.5B
| $61.5M | 2.16% | 624,435 +335,559 | +116% | +$33M |
|
|
11
Nuvalent
NUVL
$5.52B
| $59.6M | 2.1% | 840,945 +599,710 | +249% | +$42.5M |
|
12
iRhythm Technologies
IRTC
$5.46B
| $58.2M | 2.05% | 556,391 -149,000 | -21% | -$15.6M |
|
13
Apogee Therapeutics
APGE
$2.17B
| $57.5M | 2.02% | 1,540,362 | – | – |
|
14
Transmedics
TMDX
$3.92B
| $57.5M | 2.02% | 854,884 -67,216 | -7% | -$4.52M |
|
|
15
Guardant Health
GH
$8.41B
| $56.5M | 1.99% | 1,327,327 -1,520,604 | -53% | -$64.8M |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $54.1M | 1.9% | 2,458,808 +126,612 | +5% | +$2.79M |
|
17
Inspire Medical Systems
INSP
$2.77B
| $48.2M | 1.69% | 302,410 +9,000 | +3% | +$1.43M |
|
|
18
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $43.6M | 1.53% | 1,962,909 -1,489,538 | -43% | -$33.1M |
|
19
Intuitive Surgical
ISRG
$170B
| $43.6M | 1.53% | 88,000 +12,700 | +17% | +$6.29M |
|
20
Alphatec Holdings
ATEC
$2.35B
| $43.2M | 1.52% | 4,259,429 +2,939 | +0.1% | +$29.8K |
|
21
Spyre Therapeutics
SYRE
$996M
| $41.6M | 1.46% | 2,578,404 | – | – |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $38.9M | 1.37% | +439,968 | New | +$38.9M |
|
23
Dyne Therapeutics
DYN
$1.92B
| $37.9M | 1.33% | 3,621,344 +2,940,162 | +432% | +$30.8M |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $36.1M | 1.27% | 1,652,334 -446,532 | -21% | -$9.77M |
|
25
Adaptive Biotechnologies
ADPT
$2.01B
| $35.7M | 1.25% | +4,803,794 | New | +$35.7M |
|